用于复发多发性骨髓瘤的T细胞重定向疗法。
T cell redirecting therapy for relapsed multiple myeloma.
作者信息
Tan Melinda S Y, Hellou Tamer, Dingli David
机构信息
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
出版信息
Discov Oncol. 2025 Aug 18;16(1):1573. doi: 10.1007/s12672-025-03432-z.
In recent years, the utilization of immunomodulatory drugs, proteasome inhibitors and CD38 targeting monoclonal antibodies has led to significant improvements in the overall outcomes of patients with multiple myeloma. Despite these advances, relapse remains common, and until recently, the prognosis of such patients was guarded. The approval of chimeric antigen receptor (CAR) T-cells and T-cell engagers (TCE) have considerably improved the survival in these patients with triple and penta-class refractory disease. This paper reviews the clinical outcomes associated with these novel immunotherapeutic agents, including their associated toxicities, their role and optimal sequencing within the treatment landscape of multiple myeloma. The importance of supportive care in managing these patients will be discussed. Finally, we offer a perspective on emerging developments in the immunotherapy of relapsed multiple myeloma.
近年来，免疫调节药物、蛋白酶体抑制剂和靶向CD38单克隆抗体的应用显著改善了多发性骨髓瘤患者的总体预后。尽管取得了这些进展，但复发仍然很常见，直到最近，这类患者的预后仍不容乐观。嵌合抗原受体（CAR）T细胞和T细胞衔接器（TCE）的获批显著改善了这些三重和五重难治性疾病患者的生存率。本文综述了这些新型免疫治疗药物的临床疗效，包括其相关毒性、在多发性骨髓瘤治疗格局中的作用和最佳序贯方案。还将讨论支持性治疗在管理这些患者中的重要性。最后，我们对复发多发性骨髓瘤免疫治疗的新进展提出了展望。
Zotero 插件